Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Aspirin Ads Revised Under $1 Mil. FTC Settlement

This article was originally published in The Tan Sheet

Executive Summary

Bayer ads cautioning aspirin therapy "is not appropriate for everyone" and offering a free consumer education brochure will break in February magazines under a $1 mil. settlement reached with the Federal Trade Commission.

You may also be interested in...



TV Ad Disclosure Poorly Understood By Consumers - FTC Workshop

Disclosure of pertinent information in broadcast advertising is only theoretical, not actual, due to the high reading comprehension rates needed to read disclosure statements, according to attendees at a Federal Trade Commission-National Advertising Division of the Council of Better Business Bureaus workshop in Washington, D.C. May 22.

TV Ad Disclosure Poorly Understood By Consumers - FTC Workshop

Disclosure of pertinent information in broadcast advertising is only theoretical, not actual, due to the high reading comprehension rates needed to read disclosure statements, according to attendees at a Federal Trade Commission-National Advertising Division of the Council of Better Business Bureaus workshop in Washington, D.C. May 22.

Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study

Aspirin usage in outpatients with coronary artery disease without contraindications increased from 5% in 1980 to 26.2% in 1996 in a representative sample of U.S. doctors' office visits, according to a study in the March 14 issue of the American Heart Association journal Circulation.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel